Science
Mechanism of Action
This ingredient, or its structurally related active forms, modulates specific cellular pathways within the skin. Research indicates that cyclic phosphatidic acid (cPA) and lysophosphatidic acid (LPA) activate the LPAR1-Gi/o signaling cascade in human skin fibroblasts. This activation subsequently triggers the phosphatidylinositol-3 kinase (PI3K), extracellular-signal-regulated kinase (ERK), and CREB pathways, leading to an upregulation of hyaluronan synthase 2 (HAS2) gene and protein expression. The outcome is increased hyaluronic acid (HA) production, essential for maintaining skin moisture and extracellular matrix integrity. Furthermore, LPA contributes to skin barrier enhancement by promoting keratinocyte differentiation and inducing filaggrin (FLG) expression via LPAR1 and LPAR5 receptors and the RHO-ROCK-SRF pathway. It also demonstrates growth factor-like activity on fibroblasts and stimulates the production of transforming growth factors (TGF) alpha and beta in cultured human keratinocytes, supporting cellular proliferation and differentiation.
Research
Clinical Evidence
Medium confidenceN/A
Key findings
- 01 Cyclic phosphatidic acid (cPA) and lysophosphatidic acid (LPA), closely related compounds, demonstrated a dose-dependent induction of hyaluronic acid synthesis. This effect was observed at concentrations as low as 3μM and was mediated through the LPAR1-Gi/o, PI3K, ERK, and CREB signaling pathways, leading to upregulated HAS2 mRNA and protein.
Transparency
Dusting Analysis
There is no specific data to indicate that HYDROGENATED SODIUM CYCLIC LYSOPHOSPHATIDIC ACID is a commonly dusted ingredient.
The Formula
Formulation
Stability
While specific optimal pH and stability data for HYDROGENATED SODIUM CYCLIC LYSOPHOSPHATIDIC ACID are not detailed, a related compound, 1-Oleoyl lysophosphatidic acid sodium salt, is typically prepared in Phosphate-Buffered Saline (PBS) at pH 7.2. This suggests that a neutral pH environment may be favorable for the stability of related lysophosphatidic acid derivatives.
Safety
Safety Profile
Specific safety assessments for HYDROGENATED SODIUM CYCLIC LYSOPHOSPHATIDIC ACID by major regulatory bodies such as the Cosmetic Ingredient Review (CIR) or the Scientific Committee on Consumer Safety (SCCS) are not available. The FDA does not routinely conduct pre-market safety reviews for cosmetic ingredients, aside from color additives.
Your Skin
Skin Compatibility
Our Assessment
Verdict
HYDROGENATED SODIUM CYCLIC LYSOPHOSPHATIDIC ACID presents a compelling biochemical foundation for enhancing skin hydration and barrier integrity through its resemblance to potent lipid signaling molecules; however, specific clinical efficacy data, optimal usage concentrations, and direct safety assessments for this exact ingredient in skincare are currently limited, necessitating further research for definitive conclusions.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources